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USE OF OLANZAPINE AND RISPERIDONE AT 
BASELINE IN A PROSPECTIVE STUDY OF THE 
COURSE OF TREATMENT FOR SCHIZOPHRENIA
Johnstone BM1, Dulisse BK2, Loosbrock DL1, Gibson PJ1
1Health Outcomes Evaluation Group, Eli Lilly and Company, 
Indianapolis, IN, USA; 2Statistical and Mathematical Sciences, 
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, 
IN, USA
OBJECTIVES: To profile utilization of olanzapine and
risperidone at baseline in a prospective study of treat-
ment for schizophrenia, and evaluate factors associated
with the receipt of these medications. METHODS: Data
were obtained from the US Schizophrenia Care and As-
sessment Program (US-SCAP), a prospective study of
treatment for schizophrenia in six large community sys-
tems of care. The first 1,231 patients enrolled in the
study were evaluated, including 321 patients treated with
olanzapine and 231 patients treated with risperidone.
RESULTS: 45 percent of patients received olanzapine
and/or risperidone over a six-month baseline interval.
Olanzapine-treated patients received a median dose of
10.4 mg/day [mean 13.0, mode 10]. Risperidone-treated
patients received a median dose of 6.0 mg/day [mean 5.6,
mode 6]. Among patients receiving both medications, ris-
peridone was two times more likely to precede olanza-
pine than the reverse order. Patients initiating treatment
with olanzapine were significantly more likely to receive
prior treatment with clozapine and/or depot antipsychot-
ics (P  0.01) than risperidone-treated patients. Patients
treated with olanzapine only were significantly less likely
to receive antiparkinsonian or anticholinergic agents
(P  0.01) during the treatment interval than patients
treated with risperidone only. CONCLUSIONS: Dosages
of olanzapine and risperidone in this large community
sample of patients receiving usual care were consistent
with expectations from controlled studies. Olanzapine-
treated patients were more likely to receive prior thera-
pies associated with treatment resistance or noncompli-
ance than risperidone-treated patients, suggesting the
possibility of greater severity in the olanzapine treatment
group. Olanzapine-treated patients were less likely to re-
ceive antiparkinsonian or anticholinergic medications
during therapy.
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Schizophrenia affects less than 1% of the US population,
yet its treatment accounts for more than 2.5% of total
healthcare expenditures, making it the most costly illness
to treat in psychiatry. OBJECTIVES: The purpose of this
study is to document the treatment experience of patients
with schizophrenia in a managed care population.
METHODS: This study utilized an administrative claims
database from PacifiCare in California. Prescription and
encounter claims from 1/1/95–9/1/99 in California,
Texas, Oklahoma, Washington and Oregon were evalu-
ated using an intent-to-treat analysis. Only adults were
included, with 6 prior months eligibility, no antipsy-
chotic medication use in the 120 days before treatment
start (washout period), continuous antipsychotic use for
120 days, and 365 days of eligibility following treat-
ment start. RESULTS: Of the 4,388 PacifiCare members
qualifying for this analysis, only 232 (5%) had a diagno-
sis of schizophrenia in the 180 days prior to the treat-
ment start. In 4,321 (98%) of the antipsychotic treatment
episodes, a single antipsychotic agent was initiated. Of
those initiating antipsychotic mono-therapy, 3,286 (76%)
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began therapy on a conventional medication, while 1,035
(24%) started on an atypical medication. Only 67 pa-
tients initiated treatment using 2 antipsychotics simul-
taneously. Time-to-event analysis of treatment discontin-
uation (mono-atypical vs. mono-conventional vs. multi-
therapy) found that the probabilities of discontinuing
therapy differed by year of prescription. In more current
prescription years, patients initiating atypical therapy
were more likely to remain on therapy than those starting
on conventional agents. CONCLUSION: Atypical agents
appear to provide improved performance in treatment
continuation.
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USE OF ATYPICAL ANTIPSYCHOTIC 
MEDICATIONS IN A VETERANS POPULATION
Hudson T, Feng W, Owen R, Austen M
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RESEARCH OBJECTIVE: Novel antipsychotic medica-
tions have several advantages over traditional agents in
the treatment of schizophrenia. Little is known about fac-
tors that affect prescribing of novel agents. This study ex-
amines variation in novel antipsychotic prescribing at 13
VA Medical Centers from six Veterans Integrated Service
Networks (VISNs). STUDY DESIGN: Using automated
data from 13 VA Medical Centers at six VISNs, we iden-
tified 740 patients with an outpatient prescription for an-
tipsychotic medication following their last discharge with
a diagnosis of schizophrenia in 1997. Most patients
(711) were male. Approximately 46% were African
American, 46% were white, and 7% were Hispanic.
Mean age was 48.5 (range 22–89). POPULATION
STUDIED: Schizophrenic patients. PRINCIPAL FIND-
INGS: Novel antipsychotic medications were prescribed
for 46.2% of the subjects, with significant variation
among the facilities (2  24.9, df  12, P  0.015,
range 26.8–58.9%) and less significant variation among
the VISNs (2  9.85, df  5, P  0.08, range 39.5–
54.4%). About 6% of the patients (46) were given depot
antipsychotic medications. Only 1 person received both
depot and novel antipsychotic medications. Although the
study population consisted of approximately equal num-
bers of white and African American subjects, 72% (33)
of the subjects prescribed depot antipsychotics were Afri-
can Americans. White patients were more likely than
non-whites to receive novel antipsychotic medications
(OR  1.836, P  0.0002) controlling for marital status,
gender, age, and facility. CONCLUSIONS: Less than
half of patients with schizophrenia are receiving novel
antipsychotic medications in this sample. In addition,
there is significant variation among facilities as well as by
ethnicity. IMPLICATIONS FOR DELIVERY AND
PRACTICE: The variation among facilities as well as by
ethnicity suggests that prescribing practices for these
agents could be improved. Further research is needed to
determine the factors that influence these practices.
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Li J1, McCombs J1, Stimmel G2
1Department of Pharmaceutical Economic and Policy, School of 
Pharmacy, University of Southern California, Los Angeles, CA, 
USA; 2Department of Clinical Pharmacy, School of Pharmacy, 
University of Southern California, Los Angeles, CA, USA
Treatment guidelines for bipolar disorder recommend
constant drug therapy with a mood stabilizing medica-
tion and prompt drug treatment for manic and depressive
episodes. The use patterns and duration of mood stabiliz-
ing therapy in real world practice are unclear. OBJEC-
TIVES: This study documents the use patterns and dura-
tion of therapy for mood stabilizing medications used to
treat bipolar disorder patients and explores the factors
that affect compliance with drug therapy. METHODS:
Medi-Cal data covering 1993–99 were used to identify
4,813 adult bipolar patients with at least one prescrip-
tion for a mood stabilizer filled during the first 12
months of their treatment episode. Compliance was de-
fined as a medication possession ratio for mood stabiliz-
ers in excess of 0.9 during the first 12 months after the
initiation of drug therapy. Logistic regression analysis
was conducted using SAS. RESULTS: 1,765 patients
(36.7%) initiated therapy on a mood stabilizer; 612
(12.7%) and 965 (20%) used an antidepressants or an-
tipsychotic as initial therapy, respectively; 1,471 (30.6%)
used multiple medications as initial therapy. The compli-
ance rate was 12.4%. A diagnosis of bipolar-manic disor-
der significantly increased the likelihood of compliance
(odds ratio  1.74), as did a diagnosis of schizophrenia
(1.33), and initiation of therapy on an atypical antipsy-
chotic (1.47). Delays in the initiation of mood stabilizer
therapy and the selection of valproic acid as the initial
mood stabilizer significantly reduced the likelihood of
compliance (odds ratio  0.642, P  0.002 for valporic
acid). CONCLUSIONS: Current drug treatment patterns
for bipolar disorder are far from ideal. Delays in mood
stabilizer use and drug selection are important determi-
nants of mood stabilizer use patterns that are consistent
with treatment guidelines.
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Scarce data exists to characterize the nature of recent sed-
ative/hypnotic use in ambulatory patients. Clinical litera-
ture suggests that use of these agents has adverse conse-
quences related to physical and mental functioning that
may be of particular concern to older individuals. Ad-
